Zydus Lifesciences

The US FDA has granted priority review to Saroglitazar, Zydus Lifesciences' drug for treating Primary Biliary Cholangitis

In the March quarter (Q4FY26), Zydus Lifesciences reported a net profit of ₹1,272.5 crore, as compared to ₹1,170.9 crore a year ago, up 8.7 per cent

Zydus Lifesciences reported strong fourth-quarter earnings growth, supported by robust performance in India, international markets, and consumer wellness

Q4FY26 company results: Firms including Zydus Lifesciences, BASF India, PI Industries, Zee Entertainment, and Bosch Home Comfort India are also to release their January-March earnings today

Zydus Wellness Ltd on Monday reported 5.75 per cent decline in consolidated net profit at Rs 162 crore for the fourth quarter ended March 31, 2026 impacted by higher expenses and taxes. The company had posted a net profit of Rs 171.9 crore for the year-ago period, Zydus Wellness said in a regulatory filing. Total revenue from operations in the fourth quarter stood at Rs 1,484.7 crore as compared to Rs 913.1 crore in the year-ago period. Total expenses were at Rs 1,308.6 crore as against Rs 740.5 crore. Total tax expenses were also higher at Rs 15.3 crore as compared to Rs 1.5 crore in March quarter FY25. In FY26, the consolidated net profit was at Rs 197.2 crore as compared to Rs 346.9 crore a year ago. Total revenue from operations stood at Rs 3,961 crore as against Rs 2,708.9 crore. The board of directors at its meeting held on May 18, 2026 recommended a final dividend of Rs 1.20 per equity share of Rs 2 each, subject to approval of the shareholders.

The buying on the counter came after the company, through a filing, said that its board will consider a buyback in a meeting along with the financial results on Tuesday, May 19, 2026

Acquisition gives Zydus a branded-drugs commercial platform in the US and strengthens its specialty pharmaceutical presence in pain and oncology therapies

Companies including Dr. Reddy's Laboratories, Sun Pharma, Zydus Lifesciences, Natco Pharma, Alkem Laboratories, and Torrent Pharmaceuticals have developed their own formulations

Lupin and Zydus Lifesciences enter a licensing pact to co-market semaglutide injection in India, aiming to improve access to therapies for diabetes and obesity

Semaglutide is a GLP-1 receptor agonist used to treat Type 2 Diabetes and, increasingly, for weight management by helping regulate blood sugar and appetite

Zydus Lifesciences on Saturday said its innovative drug has received approval from China's National Medical Products Administration (NMPA) for its drug Desidustat tablets used for treating renal anaemia. The company has licensed its Desidustat tablets to a subsidiary of China Medical System Holdings Ltd. CMS International Development and Management Ltd, a wholly-owned subsidiary of CMS, had obtained an exclusive license for the drug from Zydus in 2020. Desidustat tablets are administered orally for treating anaemia in Chronic Kidney Disease (CKD) patients. CKD involves the gradual loss of kidney function and eventually leads to kidney failure. "We are encouraged by the NMPA's approval for marketing the drug in China. Our life-changing discoveries are driven by a commitment to improving patient outcomes and enabling healthier, more fulfilled lives, globally," Zydus Lifesciences MD Sharvil P Patel said in a statement. The company is happy to partner with CMS and is confident that th

The deal will enable the company to continue marketing its generic Mirabegron in the United States, Zydus said, adding that other terms and conditions ​of the agreement are confidential

Apex court declines to halt Zydus' biosimilar nivolumab launch, asks Bristol Myers Squibb to seek interim relief before Delhi High Court

Zydus Lifesciences posted higher Q3 profit and revenue, aided by strong growth in the US and India businesses, improved margins, and steady momentum in generics, specialty and chronic segments

Zydus Life Q3 Ebitda for the quarter was ₹1,816.4 crore, up 31 per cent Y-o-Y. Ebitda margin during the same period stood at 26.5 per cent, marking an improvement of 20 basis points

Q3FY26 company results: Firms including GlaxoSmithKline Pharmaceuticals, The Ramco Cements, Linde India, Gulf Oil Lubricants, and Bata India are also to release their October-December earnings today

Zydus Lifesciences on Friday said the US health regulator has granted Orphan Drug Designation to Desidustat, a novel oral product medication for the treatment of Sickle Cell Disease. The US Food and Drugs Administration's (USFDA) grants orphan status to support development of medicines for the treatment of rare diseases that affect fewer than 2 lakh people in the US. "This Orphan Drug Designation from the USFDA underlines the urgent medical need to develop a therapy for sickle cell disease. We believe that Desidustat can address this unmet need," Zydus Lifesciences MD Sharvil Patel said in a statement. Therapeutic options for management of Sickle Cell Disease are currently limited. A Phase II, double blind, randomised, placebo controlled, parallel, multi-centre, proof-of-concept study to evaluate the efficacy and safety of Desidustat oral tablet for treatment of SCD has been completed, and data will be published in a medical journal, the drug firm said. Orphan drug designation by

Zydus Lifesciences on Wednesday has received approval from the US health regulator to market a generic diabetes drug in the US market. The company has received tentative approval from the US Food and Drug Administration (USFDA) for Dapagliflozin Tablets in strengths of 5 mg and 10 mg, the drug firm said in a statement. Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. The company said the tablets will be manufactured at its formulation manufacturing facility at SEZ, Ahmedabad. As per the industry estimates, Dapagliflozin tablets had annual sales of USD 10,486.9 million in the US. Zydus shares on Wednesday ended 0.23 per cent up at Rs 905 apiece on BSE.

Move comes just months before nivolumab patent expiry in India on May 2, 2026

Systematix said the recent US FDA approval of Zycubo, a Menkes disease treatment marketed by Sentynl Therapeutics, significantly enhances the company's growth outlook